Form 4: Marinus Pharmaceuticals CEO Exercises Stock Options

Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, exercised stock options to acquire 50,000 shares of common stock on March 27, 2024.

Summary

• On March 27, 2024, Scott Braunstein, the Chairman and CEO of Marinus Pharmaceuticals, exercised stock options.
• This transaction involved the acquisition of 50,000 shares of common stock at a price of $4.28 per share.
• Following the transaction, Braunstein directly owns 273,512 shares of Marinus Pharmaceuticals common stock.
• Braunstein also holds options to purchase 200,000 additional shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option exercise. It doesn't inherently indicate positive or negative performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor impact on shareholders due to the increase in outstanding shares, but it's unlikely to be significant given the relatively small number of shares involved.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Scott Braunstein, stock options, Form 4, insider trading, beneficial ownership, common stock